Transplant News and Research

RSS

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

Renal research consortia receives two grants for translational research from DKF

The Dutch Kidney Foundation (DKF) awards two Consortium Grants of 1,5 million euro to renal research consortia to concentrate on translational research.

16 Sep 2010

FDA updates dosing recommendation for Valcyte medication

The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant.

16 Sep 2010

Scientists reveal techniques to extend organ transplant life

Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life.

16 Sep 2010

Virus related organ recipient deaths to be examined

After the death of three organ transplant recipients, a Victorian coroner will examine if it is possible to screen for a particular virus before donation.

15 Sep 2010

UK HealthCare announces successful kidney transplant surgery in 16-year-old

UK HealthCare announces the revitalization of its pediatric kidney transplant program with the successful transplant surgery of 16-year-old Courtney Stroud, of Carlisle, Ky. Courtney's transplant was performed Aug. 31 at Kentucky Children's Hospital.

15 Sep 2010

ThermoGenesis 2010 fourth quarter revenue increases to $7.2 million

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that revenues for the fourth quarter of fiscal 2010 were $7.2 million versus revenues of $4.0 million for the same quarter a year ago. Revenues in the third quarter of fiscal 2010 were $4.8 million.

15 Sep 2010

ThermoGenesis retains compliance with NASDAQ listing standards

ThermoGenesis Corp. a leading supplier of innovative products and services that process and store adult stem cells, said today that it has been informed by NASDAQ that the Company is in compliance with all NASDAQ listing standards, including the minimum price bid requirement.

14 Sep 2010

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Tengion, Inc., a leader in regenerative medicine, announced today the publication of a key study in the American Journal of Physiology Renal Physiology by researchers at Tengion. In the study, rodents with chronic kidney disease (CKD) were treated with healthy kidney cells to catalyze the regeneration of functional kidney tissue and delay disease progression, as evidenced by extended survival, improved kidney filtration, and reduced severity of kidney tissue pathology.

14 Sep 2010

Human cytomegalovirus cloned

A team of Welsh scientists have successfully cloned a human virus offering new hope for the treatment of potentially life-threatening diseases.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Genzyme Corporation enters into asset purchase agreement with LabCorp

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

The Virginia Commonwealth University Medical Center is the lead institution in a national clinical trial of technology that will allow artificial heart patients to recuperate, rehabilitate and wait in the comfort of their own homes until a donor heart becomes available for transplant.

10 Sep 2010

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Diplomat Specialty Pharmacy announced today they have earned a position of 554 on Inc. Magazine's exclusive, annual ranking of the fastest-growing private companies in America.

10 Sep 2010

Risk of late onset TRAS in living unrelated donor kidney recipients

Patients who have received a new kidney are significantly more likely to develop transplant renal artery stenosis (TRAS) if they are obese or over 50, according to research published in the September issue of the Journal of Renal Care.

7 Sep 2010

FDA approves IDE study to evaluate HeartWare Ventricular Assist System

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a second allotment of 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).

4 Sep 2010